TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp announced that its CEO, Dr. Patrice Rioux, will present at the UMDF’s Mitochondrial Medicine 2025 Conference, highlighting the company’s leading clinical programs in MELAS and Leigh Syndrome Spectrum. The presentation will focus on their novel thiol drug, TTI-0102, which is in Phase 2 clinical trials in Europe and the U.S. The drug is designed to enhance intracellular levels of glutathione and taurine to combat oxidative stress, a core issue in mitochondrial disorders. This announcement underscores Thiogenesis’ commitment to advancing treatments for mitochondrial diseases and may strengthen its position in the biopharmaceutical industry.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders.
Average Trading Volume: 32,360
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$36.12M
See more data about TTI stock on TipRanks’ Stock Analysis page.